Gefapixant

Gefapixant is a pharmaceutical drug developed for the treatment of chronic cough. It is a P2X3 receptor antagonist, which means it works by blocking the action of a specific protein in the body that is involved in the sensation of cough.

Mechanism of Action[edit | edit source]

Gefapixant works by blocking the P2X3 receptor, a protein found on the surface of certain nerve cells. This receptor is involved in the sensation of cough. By blocking this receptor, Gefapixant can reduce the frequency and severity of coughing.

Clinical Trials[edit | edit source]

Gefapixant has been tested in several clinical trials. In a Phase 2b trial, the drug was found to significantly reduce cough frequency in patients with chronic cough. A Phase 3 trial is currently underway to further evaluate the drug's efficacy and safety.

Side Effects[edit | edit source]

Common side effects of Gefapixant include taste disturbance, headache, and fatigue. In clinical trials, these side effects were generally mild and temporary.

Regulatory Status[edit | edit source]

As of 2021, Gefapixant is not yet approved for use by any regulatory authority. However, it is currently under review by the Food and Drug Administration (FDA) in the United States.